Bacteria as anticancer agents: bioactive metabolites, engineered platforms, and translational mechanisms
Letters in Applied Microbiology · 12.06.2026 · 79 (6)
DOI: 10.1093/lambio/ovag050 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Letters in Applied Microbiology, online erschienen am 04.06.2026. Verfasst von Manel Gharbi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Group of Bacteriology and Biotechnology Development, Laboratory of Epidemiology and Veterinary Microbiology, Pasteur Institute of Tunis, University o…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Bacteria, Biological Products, Neoplasms. Die Arbeit nennt 152 Literaturangaben.
Abstract (Originalsprache)
Bacteria represent a vast and underexplored reservoir of bioactive compounds with significant anticancer potential. Numerous bacterial taxa, particularly actinomycetes, Bacillus, Pseudomonas, and marine-derived species, produce structurally diverse metabolites exhibiting cytotoxic, cytostatic, pro-apoptotic, immunomodulatory, and anti-angiogenic activities against cancer cells. Clinically established agents such as actinomycin D and bleomycin highlight the therapeutic relevance of bacterial natural products, while recent discoveries continue to expand the repertoire of bioactive polyketides, peptides, alkaloids, and proteins. These compounds act through multiple mechanisms, including DNA intercalation, induction of apoptosis, cell cycle arrest, metabolic disruption, and modulation of the tumor microenvironment. Advances in metagenomics, genome mining, and synthetic biology have enabled the identification and activation of previously silent biosynthetic gene clusters, significantly enhancing drug discovery potential. In addition to metabolite-based anticancer agents, advances in synthetic biology have enabled the development of engineered bacterial platforms capable of selectively colonizing tumors, delivering therapeutic molecules, and activating prodrug therapies within the tumor microenvironment. Despite ongoing challenges related to toxicity, limited yield, selectivity, and clinical translation, bacterial-derived compounds remain a promising frontier in oncology. This review summarizes bacterial sources, bioactive metabolites, molecular mechanisms, preclinical and clinical applications, and future prospects for developing effective and safe anticancer strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Group of Bacteriology and Biotechnology Development, Laboratory of Epidemiology and Veterinary Microbiology, Pasteur Institute of Tunis, University of Tunis El Manar (UTM), Tunis 1002, Tunisia.
- University of Jendouba, Higher Institute of Biotechnology of Beja, 9000 Beja, Tunisia.
- University of Tunis El Manar, Tunisian institute of veterinary research, Laboratory of bacteriological research, 1006 Tunis, Tunisia.
- University of Tunis El Manar, Faculty of Medicine of Tunis, Laboratory of Antibiotic Resistance LR99ES09, 1006 Tunis, Tunisia.
ORCID-Profile: Mohamed Salah Abbassi
Zitieren
APA
Gharbi, M., & Abbassi, M. S. (2026). Bacteria as anticancer agents: bioactive metabolites, engineered platforms, and translational mechanisms. Letters in Applied Microbiology, 79(6). https://doi.org/10.1093/lambio/ovag050
Vancouver
Gharbi M, Abbassi MS. Bacteria as anticancer agents: bioactive metabolites, engineered platforms, and translational mechanisms. Letters in Applied Microbiology. 2026;79(6). doi:10.1093/lambio/ovag050
BibTeX
@article{Gharbi2026,
author = {Gharbi, Manel and Abbassi, Mohamed Salah},
title = {Bacteria as anticancer agents: bioactive metabolites, engineered platforms, and translational mechanisms},
journal = {Letters in Applied Microbiology},
year = {2026},
volume = {79},
number = {6},
doi = {10.1093/lambio/ovag050}
}
EUVIMED